Sphingolipid desaturase DEGS1 is essential for mitochondria-associated membrane integrity.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
15 05 2023
Historique:
received: 23 06 2022
accepted: 22 03 2023
medline: 16 5 2023
pubmed: 24 3 2023
entrez: 23 3 2023
Statut: epublish

Résumé

Sphingolipids function as membrane constituents and signaling molecules, with crucial roles in human diseases, from neurodevelopmental disorders to cancer, best exemplified in the inborn errors of sphingolipid metabolism in lysosomes. The dihydroceramide desaturase Δ4-dihydroceramide desaturase 1 (DEGS1) acts in the last step of a sector of the sphingolipid pathway, de novo ceramide biosynthesis. Defects in DEGS1 cause the recently described hypomyelinating leukodystrophy-18 (HLD18) (OMIM #618404). Here, we reveal that DEGS1 is a mitochondria-associated endoplasmic reticulum membrane-resident (MAM-resident) enzyme, refining previous reports locating DEGS1 at the endoplasmic reticulum only. Using patient fibroblasts, multiomics, and enzymatic assays, we show that DEGS1 deficiency disrupts the main core functions of the MAM: (a) mitochondrial dynamics, with a hyperfused mitochondrial network associated with decreased activation of dynamin-related protein 1; (b) cholesterol metabolism, with impaired sterol O-acyltransferase activity and decreased cholesteryl esters; (c) phospholipid metabolism, with increased phosphatidic acid and phosphatidylserine and decreased phosphatidylethanolamine; and (d) biogenesis of lipid droplets, with increased size and numbers. Moreover, we detected increased mitochondrial superoxide species production in fibroblasts and mitochondrial respiration impairment in patient muscle biopsy tissues. Our findings shed light on the pathophysiology of HLD18 and broaden our understanding of the role of sphingolipid metabolism in MAM function.

Identifiants

pubmed: 36951944
pii: 162957
doi: 10.1172/JCI162957
pmc: PMC10178845
doi:
pii:

Substances chimiques

Oxidoreductases EC 1.-
sphingolipid desaturase EC 1.3.-
Sphingolipids 0
DEGS1 protein, human EC 1.14.99.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NICHD NIH HHS
ID : P50 HD103538
Pays : United States

Références

Neurobiol Dis. 2020 Sep;143:105014
pubmed: 32653675
J Lipid Res. 2008 Mar;49(3):625-34
pubmed: 18073406
Clin Chim Acta. 1994 Jul;228(1):35-51
pubmed: 7955428
Biochim Biophys Acta. 2012 Oct;1822(10):1570-80
pubmed: 22800932
EMBO Rep. 2017 Jul;18(7):1150-1165
pubmed: 28507162
Trends Biochem Sci. 2016 Mar;41(3):261-273
pubmed: 26857402
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
Biophys J. 2001 May;80(5):2327-37
pubmed: 11325733
Chem Rev. 2011 Oct 12;111(10):6387-422
pubmed: 21942574
Cell Rep Med. 2020 Dec 22;1(9):100154
pubmed: 33377125
Nature. 2008 Dec 4;456(7222):605-10
pubmed: 19052620
Transl Sci Rare Dis. 2017 May 25;2(1-2):1-71
pubmed: 29152458
Nat Rev Mol Cell Biol. 2012 Oct;13(10):607-25
pubmed: 22992592
Chem Rev. 2019 Apr 24;119(8):4881-4985
pubmed: 30973011
J Lipid Res. 2019 Mar;60(3):475-483
pubmed: 30683667
J Biol Chem. 1990 May 5;265(13):7248-56
pubmed: 2332429
EMBO J. 2020 Oct 15;39(20):e103791
pubmed: 32865299
EMBO J. 2004 Nov 24;23(23):4679-89
pubmed: 15526035
Mol Neurobiol. 2019 Aug;56(8):5763-5779
pubmed: 30680690
Cells. 2020 Mar 01;9(3):
pubmed: 32121501
J Biol Chem. 2009 Feb 20;284(8):5352-61
pubmed: 19049983
Int J Mol Sci. 2018 Nov 02;19(11):
pubmed: 30400205
EMBO J. 2017 Nov 15;36(22):3356-3371
pubmed: 29018038
Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2328-2337
pubmed: 30659145
Biochim Biophys Acta. 2009 Jun;1791(6):459-66
pubmed: 19041421
Eur J Hum Genet. 2019 Nov;27(11):1668-1676
pubmed: 31186544
Cell. 2011 Nov 11;147(4):840-52
pubmed: 22035958
Cell Death Differ. 2016 Sep 1;23(9):1417-27
pubmed: 27341186
Mol Biol Cell. 2001 Aug;12(8):2245-56
pubmed: 11514614
Nat Rev Mol Cell Biol. 2019 Mar;20(3):137-155
pubmed: 30523332
Annu Rev Cell Dev Biol. 2017 Oct 6;33:491-510
pubmed: 28793795
EMBO Mol Med. 2016 Sep 01;8(9):1019-38
pubmed: 27390132
EMBO J. 2012 Nov 5;31(21):4106-23
pubmed: 22892566
Diabetologia. 2009 Dec;52(12):2612-5
pubmed: 19669729
J Clin Invest. 2019 Mar 1;129(3):1229-1239
pubmed: 30620338
Biochimie. 2014 May;100:88-94
pubmed: 23933096
Front Mol Biosci. 2021 May 10;8:673977
pubmed: 34041268
Biochem J. 2004 Sep 1;382(Pt 2):527-33
pubmed: 15144238
Anal Biochem. 2018 Jul 1;552:50-59
pubmed: 28711444
J Lipid Res. 2008 Jul;49(7):1377-87
pubmed: 18204094
Genes Dev. 2011 Jan 15;25(2):189-200
pubmed: 21245170
Methods Enzymol. 2014;547:181-97
pubmed: 25416359
Nat Cell Biol. 2001 Oct;3(10):905-12
pubmed: 11584272
Hum Mol Genet. 2013 Aug 15;22(16):3296-305
pubmed: 23604518
J Clin Med. 2017 Jul 04;6(7):
pubmed: 28677615
Diabetes. 2014 Apr;63(4):1326-39
pubmed: 24379346
Science. 2019 Jul 26;365(6451):386-392
pubmed: 31273070
Nat Genet. 2001 Mar;27(3):261-2
pubmed: 11242106
J Clin Invest. 2019 Mar 1;129(3):1240-1256
pubmed: 30620337
J Clin Invest. 2002 Nov;110(9):1301-8
pubmed: 12417569
Nat Med. 2021 Jul;27(7):1197-1204
pubmed: 34059824
Nat Rev Endocrinol. 2017 Dec;13(12):710-730
pubmed: 28849786
Nat Rev Mol Cell Biol. 2016 Feb;17(2):69-82
pubmed: 26627931
Trends Cell Biol. 2018 Jan;28(1):67-76
pubmed: 28911913
Am J Med Genet A. 2016 Jun;170(6):1603-7
pubmed: 26992161
Biochemistry. 1997 Jun 10;36(23):6960-7
pubmed: 9188692
J Biol Chem. 2002 Jul 12;277(28):25512-8
pubmed: 11937514
Science. 2011 Oct 21;334(6054):358-62
pubmed: 21885730
Chem Biol. 2010 Jul 30;17(7):766-75
pubmed: 20659689
Nat Methods. 2013 Mar;10(3):259-64
pubmed: 23396283
N Engl J Med. 2013 Dec 5;369(23):2236-51
pubmed: 24304053
Biochim Biophys Acta. 2014 Apr 4;1841(4):595-609
pubmed: 24316057
Cell Death Dis. 2018 Feb 28;9(3):328
pubmed: 29491402
Cell Death Dis. 2018 Feb 28;9(3):332
pubmed: 29491385
Science. 2018 Aug 3;361(6401):
pubmed: 30072511
Hum Mol Genet. 2016 May 1;25(9):1846-56
pubmed: 26931468
Nat Rev Cardiol. 2021 Oct;18(10):701-711
pubmed: 33772258
J Lipid Res. 2020 Jul;61(7):1025-1037
pubmed: 32350079
Science. 1965 Mar 5;147(3662):1099-107
pubmed: 14242030
Methods Mol Biol. 2021;2187:113-129
pubmed: 32770504
Cell. 2015 Jan 15;160(1-2):177-90
pubmed: 25594180
J Cell Biol. 2014 Mar 17;204(6):919-29
pubmed: 24616225

Auteurs

Laura Planas-Serra (L)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Nathalie Launay (N)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Leire Goicoechea (L)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Bénédicte Heron (B)

Department of Paediatric Neurology, Reference Centre for Neurogenetic Diseases, Armand Trousseau-La Roche Guyon University Hospital, and I2-D2 Federation, Sorbonne-Université, Paris, France.

Cristina Jou (C)

Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Neurometabolic Unit and Synaptic Metabolism Lab, Neurology and Pathology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu, and MetabERN, Barcelona, Catalonia, Spain.

Natalia Juliá-Palacios (N)

Neurometabolic Unit and Synaptic Metabolism Lab, Neurology and Pathology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu, and MetabERN, Barcelona, Catalonia, Spain.

Montserrat Ruiz (M)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Stéphane Fourcade (S)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Carlos Casasnovas (C)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

Carolina De La Torre (C)

Josep Carreras Leukaemia Research Institute Barcelona, Catalonia, Spain.

Antoinette Gelot (A)

Armand Trousseau-La Roche Guyon University Hospital, Sorbonne-Université, Paris, France.

Maria Marsal (M)

ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels, Barcelona, Catalonia, Spain.

Pablo Loza-Alvarez (P)

ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels, Barcelona, Catalonia, Spain.

Àngels García-Cazorla (À)

Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Neurometabolic Unit and Synaptic Metabolism Lab, Neurology and Pathology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu, and MetabERN, Barcelona, Catalonia, Spain.

Ali Fatemi (A)

Departments of Neurology and Pediatrics, The Kennedy Krieger Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Isidre Ferrer (I)

Department of Pathology and Experimental Therapeutics, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

Manel Portero-Otin (M)

Departament de Medicina Experimental, Universitat de Lleida-Institut de Recerca Biomedica de Lleida, Lleida, Catalonia, Spain.

Estela Area-Gómez (E)

Department of Neurology, Columbia University Medical Center, New York, New York, USA.
Centro de Investigaciones Biológicas "Margarita Salas," Madrid, Spain.

Aurora Pujol (A)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH